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Role of Signal-Averaged ECG in Predicting Results of Flecainide
Provocation Test Used in Family Screening for Brugada Syndrome
NGAI-SHING MOK, CHI-CHUNG CHOY, NGAI-YIN CHAN, AMY HO, SUET-TING LAU, YUEN-CHOI CHOI
From Cardiology Team, Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong
MOK ET AL.: Role of Signal-Averaged ECG in Predicting Results of Flecainide Provocation Test Used in Family
Screening for Brugada Syndrome. Brugada syndrome (BS) is an inherited arrhythmogenic disease with an autosomal
dominant mode of inheritance. Flecainide provocation test (FPT) has been shown to be highly sensitive and specific
in unmasking the Brugada ECG pattern in affected subjects. We sought to test if late potential (LP) in signalaveraged electrocardiogram (SAECG) is helpful in predicting the results of FPT used in family screening for BS.
The study included 17 asymptomatic Chinese subjects from 8 families (M:F 10:7, mean age 24.8±11.4 years) who
have undergone family screening for BS. All screened subjects had a normal 12-lead ECG at baseline. None had
structural heart disease. SAECG using a time domain analysis was recorded prior to the FPT. LP is defined as
positive when at least 2 of the 3 criteria are met: (1) filtered QRS duration >114ms; (2) root-mean square voltage of
terminal 40ms of QRS 20µV; (3) low-averaged signal <40µV of terminal QRS 38ms. Seven subjects had a
positive LP on SAECG. Among them 3 had a positive FPT. As for the 10 subjects with a negative LP, none had a
positive FPT. Thus in predicting the results of FPT among these subjects, LP on SAECG has a sensitivity, specificity,
positive predictive value and negative predictive value of 100%, 76.9%, 42.8% and 100% respectively. Conclusion:
LP on SAECG has a high sensitivity and negative predictive value in predicting results of FPT used in family
screening for BS. (J HK Coll Cardiol 2002;10:105-108)
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Introduction

positive and negative predictive values of SAECG in
predicting the results of FPT are calculated.

Brugada syndrome is a genetically determined
primary electrical disease characterized by a marked
S T - s e g m e n t e l e v a t i o n i n l e a d s V 1- V 3 o n
electrocardiogram (ECG) during sinus rhythm and a
propensity for life-threatening ventricular tachyarrhythmias. 1 Flecainide provocation test (FPT) has
been shown to be highly sensitive and specific in
unmasking the Brugada ECG pattern in subjects with a
concealed form of the disease2 and therefore frequently
used in family screening for the syndrome. Late
potential on signal-averaged electrocardiogram
(SAECG) is frequently recorded in patients with
Brugada syndrome3 but only rarely found among healthy
subjects. We therefore sought to study if SAECG is
helpful in predicting the results of FPT used in family
screening for Brugada syndrome in our local Chinese
population.

Methods
In Princess Margaret Hospital (PMH), FPT has
been used to identify Brugada syndrome among family
members of symptomatic patients with the syndrome if
their baseline ECG is normal or non-diagnostic. SAECG
using a time domain analysis is recorded and
echocardiogram performed. This is followed by a
FPT if no structural heart disease is found on
echocardiogram. LP is defined as positive when at least
2 of the 3 criteria are met: (1) filtered QRS duration
>114 ms; (2) root-mean square voltage of terminal
40 ms of QRS 20 µV; (3) low-averaged signal <40
µV of terminal QRS 38 ms. After an informed consent
is obtained, FPT is performed in Cardiac Care Unit
under continuous cardiac monitoring. Flecainide at a
dosage of 2 mg/kg (maximum 150 mg) is given
intravenously over 10 minutes. Leads V1 and V2 are
recorded in the 2nd and 3rd intercostal spaces in addition
to the conventional 4th intercostal space which has been
shown to enhance the sensitivity of FPT.4 A positive
FPT is defined as occurrence of terminal R wave and
>1 mm ST segment elevation in leads V1-V3 following
flecainide infusion. Subjects with a positive FPT will
be monitored for 6 hours or until the ST segment in
leads V1-V3 returns to baseline. Sensitivity, specificity,
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Results
From February 1999 to December 2001, a total
of 17 asymptomatic Chinese subjects (M:F 10:7) with
a mean age of 24.8±11.4 years have undergone family
screening for Brugada syndrome in PMH. They came
from 8 families. Each family had one proband member
suffering from Brugada syndrome (Ventricular
fibrillation in 5, recurrent syncope in 2 and
asymptomatic in 1). All 17 subjects had a normal 12lead ECG at baseline. None had structural heart disease
found on echocardiogram. Of these 17 subjects, 7 had a
positive LP on SAECG. Among these 7 subjects 3 had
a positive FPT (Figure 1A) while 4 had a negative FPT.
Among the 10 subjects with a negative LP, none had a
positive FPT (Figure 1B). Thus in predicting the results
of FPT among these subjects, LP on SAECG has a
sensitivity, specificity, positive predictive value and
negative predictive value of 100%, 76.9%, 42.8% &
100% respectively. Two subjects complained of
dizziness during flecainide infusion which rapidly
subsided upon completion of the test. Transient unifocal
ventricular premature beats were recorded in 1 subject.
No bradyarrhythmia or tachyarrhythmia was found in
any subject during FPT.

Discussion
Brugada syndrome is potentially life-threatening
disease. Symptomatic patients may have up to a 62%
chance of arrhythmia recurrence over a 4-year followup.5 As this syndrome is an inherited disease with an
autosomal dominant mode of inheritance, it is therefore
essential to screen their family members who may also
be affected and therefore predisposed to life-threatening
ventricular arrhythmias. Genetic data has linked this
syndrome to mutations in cardiac sodium channel gene
SCN5A in chromosome 3.6,7 However SCN5A mutation
can be found in only 15-25% of patients with this
syndrome.8 Genetic screening for SCN5A mutation is
therefore an insensitive test in family screening to
identify Brugada syndrome unless SCN5A mutation is
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SAECG IN FAMILY SCREENING FOR BRUGADA SYNDROME

Figure 1. Late potential (LP) on signal-averaged ECG (SAECG) predicting results of flecainide
provocation test (FPT) in family screening for Brugada syndrome (see text). (A) Positive FPT evidenced
by coved type ST-segment elevation (arrowheads) in leads V1-V2 following flecainide infusion in a subject
with a positive LP on SAECG (B) Negative FPT in a subject with a negative LP on SAECG.

already documented in probands. Moreover, genetic test
for channelopathies is expensive and not easily
accessible. Using 12-lead ECG to diagnose Brugada
syndrome among family members is easy if the typical
Brugada ECG pattern is found on their ECG during sinus
rhythm. However, dynamic changes or transient
normalization of the ST-segment may obscure the
correct diagnosis. Flecainide, a potent sodium channel
blocker, has been shown to be highly sensitive and
specific in unmasking the syndrome in affected subjects
who have normal baseline ECG. 2 It is therefore
frequently used locally9 and world-wide for the purpose
of family screening in Brugada syndrome.
LP on SAECG reflects conduction delay in the
ventricles. Although at present the role of conduction
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disturbance in the right ventricle in arrhythmogenesis
of the syndrome is a matter of some controversy, it is
well known that LP on SAECG is frequently found in
patients suffering from Brugada syndrome.3 LP can be
found among patients with Brugada syndrome
irrespective of whether the Brugada ECG pattern is
manifested or concealed. 10 Ikeda et al 11 studied LP
among patients with Brugada syndrome and found that
it can even be used as a noninvasive risk stratifier in
these patients. To date, there is as yet no study to
examine whether LP on SAECG is useful in family
screening for the syndrome. In this study, we were able
to demonstrate in this small cohort of subjects that LP
in SAECG has a 100% sensitivity and negative
predictive value in predicting the results of FPT. The
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clinical implication of these results is that in conducting
family screening for Brugada syndrome, we can start
by recording both 12-lead ECG and SAECG. If the 12lead ECG does not show any Brugada ECG pattern,
FPT should be followed to look for any concealed form
of the Brugada syndrome. But for those asymptomatic
subjects who are reluctant to undergo FPT which
requires venipuncture and intravenous drug infusion
under close cardiac monitoring, a negative LP on their
SAECG should reliably predict a negative FPT and FPT
might be spared. However, if a positive LP is found,
they should be strongly encouraged to undergo FPT.
This study has the following limitations. Firstly,
the number of tested subjects in this study is small.
Whether the results in this preliminary study apply to
family screening in all patients with Brugada syndrome
remains to be clarified in future study which should
include a larger number of subjects. Secondly, the
definitions of positive LP in SAECG and positive FPT
vary among different studies. The results of this study
are applicable only in situations where the current
definitions used in this study are adopted.

Conclusions
LP on SAECG has a high sensitivity and negative
predictive value in predicting the results of FPT used
in family screening for Brugada syndrome. SAECG
using a time domain analysis should be included as an
additional non-invasive diagnostic tool in family
screening for Brugada syndrome. Asymptomatic
subjects with a negative LP could be reassured absence
of the disease and FPT might be spared. However,
subjects with a positive LP should undergo FPT to look
for any concealed form of the syndrome.
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